Lilly, Boehringer win EU nod for Jardiance combo med; J&J sells Cordis unit to Cardinal for $2B;

@FiercePharma: ICYMI: As Bayer preps for its slim-down, a restructuring looms--but jobs are safe, CEO says. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI: Top Medicare prescribers get top payments from drugmakers: Modern Healthcare. Report | Follow @CarlyHFierce

> Eli Lilly ($LLY) and Boehringer Ingelheim won European approval for their combination diabetes pill Synjardy, which comprises the SGLT2 med Jardiance (empagliflozin) with the standard treatment metformin. Release

> Johnson & Johnson ($JNJ) agreed to sell its Cordis cardiovascular device unit to Cardinal Health ($CAH) in a $2 billion deal. Release

> Roche ($RHHBY) licensed its anemia therapy Mircera to Galenica, which will market the product in the U.S. and Puerto Rico. Report

> AMAG Pharmaceuticals ($AMAG) fell short in its FDA application for a one-dose vial of its preterm labor med Makena; the agency wants more information about procedures at its contract manufacturer. Release

> Bayer Healthcare's Indonesia unit is beefing up its warehousing and manufacturing in hopes of exporting to at least 50 countries within three years. Report

Medical Device News

@FierceMedDev: Roche's Ventana teams up with Halozyme for pancreatic cancer companion Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Pacira's liposomal-encased bupivacaine gets positive reviews at breast cancer conference. FierceDrugDelivery report | Follow @VarunSaxena2

@EmilyWFierce: $SQNM is consolidating its labs. Release | Follow @EmilyWFierce

> Freedom Meditech, maker of diabetes eye scanner, raises $4.8M in Series C round. Article

> WSJ: J&J faces FBI probe over power morcellator devices. Report

Biotech News

@FierceBiotech: The White House draws the line against CRISPR/Cas9-designed embryos. More from FierceBiotechResearch | Follow @FierceBiotech

@JohnCFierce: Seres ($MCRB), joins $ADAP, $ADRO, $CDTX, $JUNO, Molecular Partners and $ONCE among the 2014 Fierce 15 biotechs to go for an IPO. | Follow @JohnCFierce

> Wall Street's open for biotech business, and Europe is taking notice. Item

> Booming Gilead is opening new labs, planning fresh hires in R&D blitz. Report

> Atlas' Padlock scoops up some GlaxoSmithKline assets in autoimmunity. Article

> A well-connected Pronutria revs up amino acid research with $39M C round. Story

Vaccines News

> World Health Assembly passes resolution on vaccine pricing, transparency. Item

> Serum Institute, Cipla partner to market flu vaccine in India. More

> Abivax seeks cash to bring Cuban-discovered HepB vaccine to the world. Story

> Hold the offer: Bavarian Nordic declares it's not for sale. Article

> Regeneus gets green light to move personalized cancer vaccine into PhI. Report

CRO News

> Parexel rejigs its randomization tech with an eye on speed. Item

> BioClinica partners up for risk-based management. More

> Ergomed snags a postmarketing firm with its eye on pharmacovigilance. Article

> EMA still wants 700 GVK-related drugs off the market. Story

> Quintiles homes in on Asian biotech with its latest offering. Report

Pharma Manufacturing News

> Bayer set to spend $3.4M this year to expand its Indonesian operations. Story

> Report: Claris Lifesciences injectables sale may hit roadblock by FDA Form 483. Item

> Aurobindo Pharma submits abbreviated application to FDA for HIV drug production. News

> Gerresheimer Glass to close NJ pharmaceutical bottle plant this summer. Article

> Gilead Sciences plans $100M expansion of Edmonton plant. Report

Pharma Asia News

> Singapore clinical hub to work with Visterra on dengue candidate. More

> TPP negotiators said to be zeroing in on clearing IP snags. Story

> Japan's cabinet tells health minister to dig deeper on costs. Article

> China to charge $102K for drug, device registration in first hike in two years. Item

> Russia makes it easier to skirt imported drug sale norms. Report

And Finally... Pandora's ($P) chief musicologist is working with Memorial Sloan Kettering Cancer Center on music therapy specifically for cancer patients. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.